US Patent

US12133844 — Methods of treating epithelioid cell tumors

Method of Use · Assigned to Abraxis Bioscience LLC · Expires 2036-06-29 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating epithelioid cell tumors, such as PEComa, using nanoparticles containing an mTOR inhibitor and albumin.

USPTO Abstract

The present invention provides methods and compositions for treating epithelioid cell tumors (such as a PEComa) by administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin.

Drugs covered by this patent

Rapamune (sirolimus) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4040`	—	Rapamune

Patent Metadata

Patent number: US12133844
Jurisdiction: US
Classification: Method of Use
Expires: 2036-06-29
Drug substance claim: No
Drug product claim: No
Assignee: Abraxis Bioscience LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.